NSABP Members' Area   Password Protected - Access   Limited to NSABP Participating   Institutions Only NSABP Foundation, Inc. General NSABP Information   Financial Conflicts of      Interest Policy   Contact the NSABP   Employment Clinical Trials Information   Clinical Trials Overview   Protocol Chart   Never Say Lost Treatment Trials Information   Protocol B-51   Protocol B-52   Protocol B-53/S1207   Protocol B-55/BIG 6-13 Prevention Trials Information   Protocol P-1 - BCPT   Protocol P-2 - STAR To report problems, ask questions or make comments, please send e-mail to: Webmaster@nsabp.pitt.edu

Annotated Bibliography of NSABP Publications Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-year Results From National Surgical Adjuvant Breast and Bowel Project B-18 Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B Journal of the National Cancer Institute Monogr (30):96-102, 2001 Abstract National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was initiated in 1988 to determine whether four cycles of doxorubicin/cyclophosphamide given preoperatively improve survival and disease-free survival (DFS) when compared with the same chemotherapy given postoperatively. Secondary aims included the evaluation of preoperative chemotherapy in downstaging the primary breast tumor and involved axillary lymph nodes, the comparison of lumpectomy rates and rates of ipsilateral breast tumor recurrence (IBTR) in the two treatment groups, and the assessment of the correlation between primary tumor response and outcome. Initially published findings were based on a follow-up of 5 years; this report updates results through 9 years of follow-up. There continue to be no statistically significant overall differences in survival or DFS between the two treatment groups. Survival at 9 years is 70% in the postoperative group and 69% in the preoperative group (P =.80). DFS is 53% in postoperative patients and 55% in preoperative patients (P =.50). A statistically significant correlation persists between primary tumor response and outcome, and this correlation has become statistically stronger with longer follow-up. Patients assigned to preoperative chemotherapy received notably more lumpectomies than postoperative patients, especially among patients with tumors greater than 5 cm at study entry. Although the rate of IBTR was slightly higher in the preoperative group (10.7% versus 7.6%), this difference was not statistically significant. Marginally statistically significant treatment-by-age interactions appear to be emerging for survival and DFS, suggesting that younger patients may benefit from preoperative therapy, whereas the reverse may be true for older patients. National Surgical Adjuvant Breast and Bowel Project (NSABP), 320 E. North Ave., Pittsburgh, PA 15212, USA.